Log in · Sign up
| Metric | 2025Q2 | 2025Q4 | 2026Q2 |
|---|---|---|---|
| Earnings from operations 10-Q 2026Q2 statement of operations (comparative) | 5,150$M | 7,991$M | |
| First-half favorable prior-year development 10-Q 2026Q2 Note 4 (comparative) | 320$M | 1,250$M | |
| Medical care ratio 10-Q 2026Q2 MD&A | 89.4% | 86.7% | |
| Medical costs payable 10-Q 2026Q2 Note 4 (2025-12-31) | 39,337$M | 38,930$M | |
| Net earnings attributable to shareholders 10-Q 2026Q2 statement of operations (comparative) | 3,406$M | 5,484$M | |
| Operating margin 10-Q 2026Q2 MD&A | 7.1% | ||
| Quarterly buybacks XBRL PaymentsForRepurchaseOfCommonStock | 0$M | ||
| Quarterly operating cash flow XBRL | 8,910$M | ||
| Quarterly revenue 10-Q 2026Q2 statement of operations (comparative) | 111,616$M | 112,032$M |